{"hands_on_practices": [{"introduction": "Accurate measurement of Breslow thickness is the cornerstone of primary tumor (T) staging in malignant melanoma. However, histopathologic features like ulceration can create ambiguity in how this measurement is performed. This exercise focuses on applying the specific, nuanced rules from the AJCC staging manual to determine the correct Breslow thickness in a complex scenario, a foundational skill for all subsequent staging and management decisions [@problem_id:4455696].", "problem": "A wide local excision specimen of a cutaneous malignant melanoma shows a central zone of ulceration measuring approximately $3~\\text{mm}$ in diameter. On histopathology, an ocular micrometer yields the following calibrated vertical measurements to the deepest invasive melanoma cell: beneath the ulcerated surface, the perpendicular distance from the base of the ulcer to the deepest melanoma cell is $0.7~\\text{mm}$; in an adjacent area with intact epidermis, the perpendicular distance from the top of the epidermal granular layer to the deepest melanoma cell is $0.6~\\text{mm}$. There are no microsatellites and the lesion is confined to the primary site without clinical or pathologic nodal involvement.\n\nWhich measurement should be used to assign the primary tumor $T$ category according to contemporary melanoma staging, and what is the resulting $T$ subcategory when ulceration is present? Choose the single best option and provide a justification consistent with accepted staging principles in dermatology and venereology.\n\nA. Use $0.6~\\text{mm}$ (intact epidermis area) because ulceration distorts thickness; assign $T1a$.\n\nB. Use $0.7~\\text{mm}$ (beneath ulcer) because the greatest Breslow thickness governs $T$; assign $T1b$ due to ulceration.\n\nC. Use the mean of the two measurements, $0.65~\\text{mm}$; assign $T1b$.\n\nD. Use $0.7~\\text{mm}$ but assign $T1a$ because ulceration does not affect $T$ subcategorization when thickness is less than $1.0~\\text{mm}$.\n\nE. Use $0.6~\\text{mm}$ and assign $T1b$ only if the mitotic rate is at least $1/\\text{mm}^2$; otherwise $T1a$.", "solution": "The user-provided problem statement has been evaluated for validity and is deemed sound. The problem is scientifically grounded in the principles of dermatopathology and oncologic staging, specifically for cutaneous malignant melanoma. It is well-posed, objective, and contains all necessary information to arrive at a unique solution based on established clinical guidelines.\n\nThe problem requires the determination of the correct T category for a cutaneous malignant melanoma based on histopathological findings. The principles governing this are laid out in the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, which provides the contemporary standard for melanoma staging.\n\n**Step 1: Identification of the Correct Breslow Thickness**\nThe primary determinant of the T category is the Breslow thickness, defined as the vertical dimension of the melanoma from the granular layer of the epidermis to the deepest point of tumor invasion. The AJCC staging guidelines provide two critical rules relevant to this problem:\n1.  **Rule for Ulceration:** In the presence of ulceration, the measurement is taken from the base of the ulcer to the deepest invasive melanoma cell.\n2.  **Rule for Maximum Thickness:** The greatest tumor thickness found anywhere on the microslides of the primary lesion is the value recorded as the Breslow thickness.\n\nThe problem provides two measurements:\n-   Measurement 1: $0.7~\\text{mm}$, taken from the base of the ulcer.\n-   Measurement 2: $0.6~\\text{mm}$, taken from the granular layer in an adjacent, non-ulcerated area.\n\nAccording to the staging rules, both measurement techniques are appropriate for their respective locations (ulcerated vs. non-ulcerated). However, the definitive Breslow thickness for the entire lesion is the maximum of these valid measurements.\n$$ \\text{Breslow Thickness} = \\max(0.7~\\text{mm}, 0.6~\\text{mm}) = 0.7~\\text{mm} $$\nTherefore, the correct Breslow thickness to be used for staging is $0.7~\\text{mm}$.\n\n**Step 2: Assignment of the T Category and Subcategory**\nThe T category is determined by the Breslow thickness and the presence or absence of ulceration. According to the AJCC 8th Edition staging criteria:\n-   A tumor with a Breslow thickness $\\le 1.0~\\text{mm}$ is classified as T1.\nSince our calculated Breslow thickness is $0.7~\\text{mm}$, the lesion is categorized as T1.\n\nThe T1 category is further subcategorized as T1a or T1b:\n-   **T1a:** Breslow thickness $ 0.8~\\text{mm}$ without ulceration.\n-   **T1b:** Breslow thickness $ 0.8~\\text{mm}$ with ulceration, **OR** Breslow thickness $\\ge 0.8~\\text{mm}$ and $\\le 1.0~\\text{mm}$ (with or without ulceration).\n\nIn this case:\n-   The Breslow thickness is $0.7~\\text{mm}$, which is $ 0.8~\\text{mm}$.\n-   The problem explicitly states the presence of ulceration.\n\nBased on these two facts, the lesion fits the criterion for T1b: thickness $ 0.8~\\text{mm}$ with ulceration. Thus, the correct staging is T1b.\n\n**Step 3: Evaluation of Provided Options**\n\n**A. Use $0.6~\\text{mm}$ (intact epidermis area) because ulceration distorts thickness; assign $T1a$.**\nThis option is incorrect. The staging guidelines explicitly require measuring from the base of an ulcer if present and using the maximum thickness found. It incorrectly uses the smaller measurement of $0.6~\\text{mm}$. Furthermore, assigning T1a is incorrect because ulceration is present, which is a criterion for a 'b' subcategory.\n**Verdict: Incorrect.**\n\n**B. Use $0.7~\\text{mm}$ (beneath ulcer) because the greatest Breslow thickness governs $T$; assign $T1b$ due to ulceration.**\nThis option is correct. It correctly identifies that the greatest thickness ($0.7~\\text{mm}$) should be used, which in this case is the measurement taken from the base of the ulcer. It also correctly assigns the T1b subcategory based on a thickness of $0.7~\\text{mm}$ ($0.8~\\text{mm}$) in the presence of ulceration.\n**Verdict: Correct.**\n\n**C. Use the mean of the two measurements, $0.65~\\text{mm}$; assign $T1b$.**\nThis option is incorrect. Staging protocols do not involve averaging measurements. The maximum thickness is the sole accepted value. The Breslow thickness is not $0.65~\\text{mm}$.\n**Verdict: Incorrect.**\n\n**D. Use $0.7~\\text{mm}$ but assign $T1a$ because ulceration does not affect $T$ subcategorization when thickness is less than $1.0~\\text{mm}$.**\nThis option is incorrect. While it correctly identifies the thickness to be used ($0.7~\\text{mm}$), its rationale and conclusion are flawed. The presence of ulceration is a major prognostic factor and is a primary criterion for defining the 'b' subcategory in T1 tumors.\n**Verdict: Incorrect.**\n\n**E. Use $0.6~\\text{mm}$ and assign $T1b$ only if the mitotic rate is at least $1$ per $\\text{mm}^2$; otherwise $T1a$.**\nThis option is incorrect. First, it uses the wrong thickness ($0.6~\\text{mm}$). Second, it references mitotic rate as a criterion for T subcategorization. In the contemporary AJCC 8th Edition, mitotic rate is no longer a T-category defining feature, although it remains a prognostic factor. The presence of ulceration itself is sufficient to assign the T1b category for a tumor $ 0.8~\\text{mm}$ thick. This option reflects outdated criteria from the AJCC 7th Edition and applies them incorrectly.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{B}$$", "id": "4455696"}, {"introduction": "After determining the individual T, N, and M components, the next step is to synthesize them into an overall prognostic stage group. This process is not always intuitive, as certain high-risk features of the primary tumor can result in a higher stage even in the absence of nodal or distant disease. This practice provides a direct application of the AJCC 8th edition staging tables, reinforcing your ability to translate a complete TNM classification into a final stage that accurately reflects prognosis [@problem_id:4455639].", "problem": "A patient presents with a primary cutaneous melanoma on the posterior trunk measuring $4.2~\\text{mm}$ in Breslow thickness. Histopathology confirms ulceration. Sentinel Lymph Node Biopsy (SLNB) shows no nodal metastasis, and cross-sectional imaging finds no evidence of distant disease. Use the American Joint Committee on Cancer (AJCC) 8th edition principles that stage primary cutaneous melanoma by combining primary tumor category (thickness and ulceration), regional nodal status, and distant metastasis, to determine the overall stage group and the specific Stage $\\mathrm{II}$ subclass for this tumor, given that the primary tumor category is T4b, nodal status is N0, and there is no distant metastasis (M0). Which of the following is the correct overall stage?\n\nA. Stage $\\mathrm{IIB}$  \nB. Stage $\\mathrm{IIC}$  \nC. Stage $\\mathrm{IIIA}$  \nD. Stage $\\mathrm{IV}$", "solution": "The problem statement is first subjected to a rigorous validation process.\n\nThe givens are:\n- A primary cutaneous melanoma with a Breslow thickness of $4.2~\\text{mm}$.\n- The tumor is ulcerated.\n- Sentinel Lymph Node Biopsy (SLNB) is negative for nodal metastasis.\n- Cross-sectional imaging is negative for distant metastasis.\n- The staging system to be used is the American Joint Committee on Cancer (AJCC) 8th edition.\n- The derived pathologically-staged components are provided as: T4b, N0, and M0.\n\nThe problem is validated as follows:\n1.  **Scientific Grounding**: The problem is grounded in the established principles of oncologic staging for cutaneous melanoma as defined by the AJCC 8th edition, which is the international standard. The provided information is internally consistent: a Breslow thickness of $4.2~\\text{mm}$ is greater than $4.0~\\text{mm}$, which corresponds to the T4 category. The presence of ulceration correctly assigns the 'b' modifier, resulting in T4b. A negative SLNB corresponds to N0, and negative imaging for distant disease corresponds to M0. All data are factually and scientifically sound.\n2.  **Well-Posedness**: The problem is well-posed. It provides a complete TNM (Tumor, Node, Metastasis) classification (T4b N0 M0) and asks for the corresponding overall stage group. The AJCC system is designed to map any valid TNM combination to a unique stage group.\n3.  **Objectivity**: The language is clinical and precise, free from ambiguity or subjective content.\n\nThe problem statement is therefore deemed valid. The solution can proceed.\n\nThe task is to determine the overall stage of a primary cutaneous melanoma based on its TNM classification according to the AJCC 8th edition staging manual. The provided classification is T4b N0 M0.\n\nThe components are defined as:\n- **T (Primary Tumor)**: T4b indicates a primary tumor with a Breslow thickness greater than $4.0~\\text{mm}$, with ulceration. The given thickness of $4.2~\\text{mm}$ is consistent with this classification.\n- **N (Regional Nodes)**: N0 indicates no evidence of regional lymph node metastasis, which is consistent with a negative SLNB result.\n- **M (Distant Metastasis)**: M0 indicates no evidence of distant metastasis, consistent with negative cross-sectional imaging.\n\nThe AJCC 8th edition combines these TNM components into prognostic stage groups. The relevant stage groups for a primary tumor with N0 and M0 status are Stage I and Stage II.\n\n- **Stage I**:\n    - Stage IA: T1a N0 M0\n    - Stage IB: T1b N0 M0 or T2a N0 M0\n- **Stage II**:\n    - Stage IIA: T2b N0 M0 or T3a N0 M0\n    - Stage IIB: T3b N0 M0 or T4a N0 M0\n    - Stage IIC: T4b N0 M0\n- **Stage III**: Involves any regional node metastasis (N1, N2, or N3) with no distant metastasis (M0).\n- **Stage IV**: Involves any distant metastasis (M1).\n\nThe patient's classification is T4b N0 M0. According to the AJCC 8th edition staging table, this combination corresponds directly to Stage IIC. The question asks for the overall stage, which is thus Stage IIC.\n\nNow, each option will be evaluated against this derivation.\n\n**A. Stage $\\mathrm{IIB}$**\nStage $\\mathrm{IIB}$ is defined by the TNM combinations T3b N0 M0 or T4a N0 M0.\n- T3b: Tumor thickness $> 2.0~\\text{mm}$ and $\\le 4.0~\\text{mm}$, with ulceration.\n- T4a: Tumor thickness $> 4.0~\\text{mm}$, without ulceration.\nThis patient's tumor category is T4b (thickness $> 4.0~\\text{mm}$ with ulceration). Therefore, Stage $\\mathrm{IIB}$ is **Incorrect**.\n\n**B. Stage $\\mathrm{IIC}$**\nStage $\\mathrm{IIC}$ is defined by the TNM combination T4b N0 M0. This precisely matches the patient's classification. Therefore, Stage $\\mathrm{IIC}$ is **Correct**.\n\n**C. Stage $\\mathrm{IIIA}$**\nStage $\\mathrm{IIIA}$ is the lowest substage of Stage III. All Stage III melanomas, by definition, have regional lymph node metastasis (N-category $\\ge$ N1) and no distant metastasis (M0). This patient is N0. Therefore, Stage $\\mathrm{IIIA}$ is **Incorrect**.\n\n**D. Stage $\\mathrm{IV}$**\nStage $\\mathrm{IV}$ is defined by the presence of distant metastasis (M-category = M1). This patient is M0. Therefore, Stage $\\mathrm{IV}$ is **Incorrect**.", "answer": "$$\\boxed{B}$$", "id": "4455639"}, {"introduction": "Oncologic staging is ultimately a tool to guide clinical decision-making. This problem moves from theoretical staging to practical application, focusing on the critical decision of whether to offer a Sentinel Lymph Node Biopsy (SLNB). It requires you to integrate knowledge of T-staging, risk factors, and evidence-based guidelines to construct a quantitative risk-benefit analysis, mirroring the complex reasoning required in modern melanoma management [@problem_id:4455648].", "problem": "A $35$-year-old patient presents with a primary cutaneous melanoma on the forearm. Histopathology shows a Breslow thickness of $0.7\\,\\mathrm{mm}$, presence of ulceration, a mitotic rate of $3/\\mathrm{mm}^2$, no lymphovascular invasion identified, and negative peripheral and deep margins on the initial diagnostic excision. There is no clinically palpable lymphadenopathy. The patient is otherwise healthy. You plan a wide local excision with an appropriate margin. Using the foundational definitions of the American Joint Committee on Cancer (AJCC) 8th edition staging that categorize primary tumor stage by measured Breslow thickness and the presence or absence of ulceration, and widely accepted guideline principles from bodies such as the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) that consider Sentinel Lymph Node Biopsy (SLNB) when the estimated risk of nodal metastasis exceeds a clinically meaningful threshold, select the single best option that most appropriately constructs a quantitative risk-benefit argument for and against SLNB in this patient and provides a recommendation.\n\nA. Offer SLNB at the time of wide local excision, explaining that ulceration upstages a thin melanoma of $0.8\\,\\mathrm{mm}$ to $\\mathrm{T1b}$ under AJCC 8th edition, that thin ulcerated melanomas have an estimated sentinel node positivity risk on the order of $5\\%-10\\%$ (further increased by younger age and a mitotic rate of $3/\\mathrm{mm}^2$), and that the morbidity of upper-extremity SLNB is relatively low (overall complication rate approximately $5\\%-10\\%$, with lymphedema risk roughly $1\\%-5\\%$), thereby justifying SLNB to obtain accurate pathologic nodal staging and potential eligibility for adjuvant systemic therapy if positive.\n\nB. Do not offer SLNB because the melanoma is $0.8\\,\\mathrm{mm}$ thick, and thickness below $1.0\\,\\mathrm{mm}$ independently implies a nodal metastasis risk $5\\%$; proceed with wide local excision alone, reserving nodal surgery for clinical recurrence.\n\nC. Proceed directly to prophylactic completion lymph node dissection of the axilla at the time of wide local excision, as occult nodal disease risk is nontrivial in ulcerated melanomas and immediate clearance prevents subsequent nodal relapse more effectively than SLNB.\n\nD. Defer SLNB unless the mitotic rate is $\\geq 10/\\mathrm{mm}^2$, because in thin melanomas mitotic rate is the primary determinant of nodal risk; with a mitotic rate of $3/\\mathrm{mm}^2$, the expected sentinel node positivity rate is $2\\%$, so observation after wide local excision is preferred.", "solution": "The patient presents with a primary cutaneous melanoma of the forearm. The goal is to determine the most appropriate management regarding the regional lymph nodes, specifically the role of sentinel lymph node biopsy (SLNB), based on the provided histopathological and clinical data and current oncology guidelines.\n\n**Step 1: Problem Validation**\nThe problem statement provides a detailed clinical scenario concerning a $35$-year-old patient with a newly diagnosed melanoma. The provided data includes: patient age ($35$), tumor location (forearm), Breslow thickness ($0.7\\,\\mathrm{mm}$), presence of ulceration, mitotic rate ($3/\\mathrm{mm}^2$), negative lymphovascular invasion, negative surgical margins, and no clinically palpable lymphadenopathy. The problem references specific, real-world clinical standards, namely the American Joint Committee on Cancer (AJCC) staging manual, 8th edition, and principles from guidelines like the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO). The question asks for a quantitative risk-benefit analysis to guide the decision on SLNB.\n\nThe problem is scientifically grounded in the established principles of dermatologic oncology. It is well-posed, providing sufficient data to apply the referenced guidelines and reach a logical conclusion. The language is objective and clinical. The problem is neither trivial nor ill-posed; it addresses a common but nuanced clinical decision point. All data are consistent and plausible. Therefore, the problem statement is valid.\n\n**Step 2: Staging the Primary Tumor (T Stage)**\nAccording to the AJCC 8th edition staging system for cutaneous melanoma, the T stage is determined by the tumor's Breslow thickness and the presence or absence of ulceration.\n- The Breslow thickness is $0.7\\,\\mathrm{mm}$.\n- Ulceration is present.\n\nThe T stage categories for thin melanomas ($\\leq 1.0\\,\\mathrm{mm}$) are:\n- **T1a**: Tumor thickness $0.8\\,\\mathrm{mm}$ without ulceration.\n- **T1b**: Tumor thickness $0.8\\,\\mathrm{mm}$ with ulceration, OR tumor thickness $0.8-1.0\\,\\mathrm{mm}$ (with or without ulceration).\n\nIn this case, the tumor is $0.7\\,\\mathrm{mm}$ thick (which is $0.8\\,\\mathrm{mm}$) and ulceration is present. Therefore, the primary tumor is classified as **$\\mathrm{T1b}$**. The full clinical stage, assuming no distant metastasis, is T1bN0M0, which corresponds to AJCC Prognostic Stage Group IB.\n\n**Step 3: Evaluating the Indication for Sentinel Lymph Node Biopsy (SLNB)**\nCurrent clinical practice guidelines (e.g., NCCN, ESMO) recommend that SLNB should be discussed and offered to patients whose risk of occult nodal metastasis is sufficiently high to warrant the procedure. A commonly accepted threshold for this risk is approximately $5\\%$.\n- The guidelines specifically recommend offering SLNB for patients with $\\mathrm{T1b}$ melanomas. This patient's melanoma is staged as $\\mathrm{T1b}$.\n- The patient also has other features that, while not primary staging criteria in AJCC 8th edition, are known adverse prognostic factors that contribute to the overall risk of nodal metastasis. These include a mitotic rate of $3/\\mathrm{mm}^2$ (a rate $\\geq 1/\\mathrm{mm}^2$ is considered adverse) and younger patient age ($35$ years).\n- The estimated risk of sentinel lymph node positivity for thin ($\\leq 1.0\\,\\mathrm{mm}$) but ulcerated melanomas ($\\mathrm{T1b}$) is in the range of $5\\%-10\\%$, which meets the threshold for considering SLNB.\n\n**Step 4: Risk-Benefit Analysis of SLNB**\nA decision to perform SLNB requires weighing the benefits of the procedure against its potential risks and morbidities.\n- **Benefits**:\n    1.  **Accurate Staging**: SLNB provides precise pathological information on the status of the regional lymph node basin, which is the single most powerful prognostic factor for patients with melanoma. A positive SLNB would upstage the patient to Stage III.\n    2.  **Guiding Adjuvant Therapy**: Patients with Stage III melanoma (node-positive disease) are candidates for adjuvant systemic therapy (e.g., immune checkpoint inhibitors or targeted therapy for BRAF-mutated tumors). These therapies have been demonstrated to significantly improve relapse-free survival. Without nodal staging via SLNB, a patient with micrometastatic disease would not be identified and offered this potentially life-altering treatment.\n- **Risks/Morbidity**:\n    1.  SLNB is an invasive surgical procedure with potential complications, including seroma, hematoma, infection, and nerve injury leading to numbness or pain.\n    2.  The most significant long-term risk is lymphedema (chronic swelling of the limb).\n    3.  For a primary tumor on the forearm, the SLNB is typically performed on the axillary lymph nodes. The morbidity of an axillary SLNB is relatively low. The overall complication rate is generally cited as being in the $5\\%-10\\%$ range, and the risk of developing clinically significant lymphedema is low, approximately $1\\%-5\\%$.\n\n**Conclusion of Analysis**: The patient has a $\\mathrm{T1b}$ melanoma with a risk of nodal metastasis of approximately $5\\%-10\\%$. The benefits of identifying a positive node—accurate prognostication and eligibility for adjuvant therapy—are substantial. The risks of the SLNB procedure, particularly for an upper-extremity primary, are present but relatively low. Therefore, based on current evidence and guidelines, offering SLNB is the standard of care for this patient.\n\n**Step 5: Evaluation of Options**\n\n*   **A. Offer SLNB at the time of wide local excision, explaining that ulceration upstages a thin melanoma of $0.8\\,\\mathrm{mm}$ to $\\mathrm{T1b}$ under AJCC 8th edition, that thin ulcerated melanomas have an estimated sentinel node positivity risk on the order of $5\\%-10\\%$ (further increased by younger age and a mitotic rate of $3/\\mathrm{mm}^2$), and that the morbidity of upper-extremity SLNB is relatively low (overall complication rate approximately $5\\%-10\\%$, with lymphedema risk roughly $1\\%-5\\%$), thereby justifying SLNB to obtain accurate pathologic nodal staging and potential eligibility for adjuvant systemic therapy if positive.**\n    This option is entirely consistent with the analysis. It correctly stages the tumor as $\\mathrm{T1b}$, accurately quantifies both the risk of nodal disease and the morbidity of the procedure, and correctly states the modern rationale for performing SLNB (staging and guidance for adjuvant therapy). **Correct**.\n\n*   **B. Do not offer SLNB because the melanoma is $0.8\\,\\mathrm{mm}$ thick, and thickness below $1.0\\,\\mathrm{mm}$ independently implies a nodal metastasis risk $5\\%$; proceed with wide local excision alone, reserving nodal surgery for clinical recurrence.**\n    This option incorrectly dismisses the significance of ulceration. The AJCC 8th edition staging system and all major guidelines explicitly incorporate ulceration as a key risk factor that upstages the tumor and warrants consideration of SLNB, even in thin melanomas. The premise that a thickness of $1.0\\,\\mathrm{mm}$ *independently* implies a low risk is flawed, as it ignores other critical prognostic variables. **Incorrect**.\n\n*   **C. Proceed directly to prophylactic completion lymph node dissection of the axilla at the time of wide local excision, as occult nodal disease risk is nontrivial in ulcerated melanomas and immediate clearance prevents subsequent nodal relapse more effectively than SLNB.**\n    This recommends an obsolete and overly aggressive procedure. Prophylactic (or elective) lymph node dissection (ELND) has been replaced by the far less morbid SLNB procedure, which was shown by the MSLT-I trial to provide equivalent melanoma-specific survival. Furthermore, the MSLT-II trial showed that even for patients with a positive sentinel node, immediate completion lymph node dissection does not improve survival over active surveillance. Recommending a direct completion dissection for a clinically node-negative patient is contrary to all modern evidence and standards of care. **Incorrect**.\n\n*   **D. Defer SLNB unless the mitotic rate is $\\geq 10/\\mathrm{mm}^2$, because in thin melanomas mitotic rate is the primary determinant of nodal risk; with a mitotic rate of $3/\\mathrm{mm}^2$, the expected sentinel node positivity rate is $2\\%$, so observation after wide local excision is preferred.**\n    This option incorrectly prioritizes mitotic rate over ulceration, which is a primary determinant of the T stage. While mitotic rate is a prognostic factor, it is not considered the *primary* determinant for the SLNB decision in AJCC 8th edition; Breslow thickness and ulceration are. The proposed mitotic rate threshold of $\\geq 10/\\mathrm{mm}^2$ is arbitrary and not supported by guidelines. The claim that the risk is $2\\%$ with a mitotic rate of $3/\\mathrm{mm}^2$ in the presence of ulceration is unsubstantiated and contradicts established risk estimates. **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "4455648"}]}